1 September 2024
Starpharma receives $4.7M R&D tax incentives
Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditures, following the lodgement of the Company’s annual income tax return.
The R&D tax refund relates to eligible Australian R&D expenditure, and previously announced overseas findings relating to Starpharma’s VivaGel®, and DEP™ docetaxel clinical programs.
Commenting on the refund, Starpharma CEO Dr Jackie Fairley said:
“The R&D tax incentive allows Starpharma to confidently advance development of its proprietary products including the clinical programs for VivaGel® and DEPTM docetaxel. In the case of DEP™ docetaxel, it supports the conduct of the clinical trial in Australia with the additional benefit that Australian patients will be the first in the world to have access to Starpharma’s improved version of the widely used cancer drug, docetaxel.”
Download ASX Announcement: Starpharma receives $4.7M R&D tax incentive ( pdf file, 335kb)